secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K
Filed at:   2025-06-25T23:59:59+00:00
Accession:  0000950170-25-089949
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assembly Bio reports positive Phase 1b topline results for ABI-4334 in chronic HBV; Gilead opt-in triggered
--------------------------------------------------------------------------------

- Mean HBV DNA decline of 3.2 log10 IU/mL over 28 days in 400 mg cohort (2.9 logs in 150 mg cohort).
- Favorable safety: no serious AEs or discontinuations; two grade 3 lab abnormalities resolved with continued dosing.
- Half-life supports once-daily oral dosing; exposure at both doses achieved double-digit multiples over target EC50.
- Data triggers Gilead's right to opt-in for exclusive license after review of option data package.
- ABI-4334 shows potential to inhibit viral replication at 150 mg and cccDNA formation at higher doses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000095017025089949/0000950170-25-089949-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000095017025089949/asmb-20250625.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-089949

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer